South-east Asian countries are emerging as preferable destination for India's pharma companies to expand their business as they share similar patient population and disease profile and moreover, have a conducive environment for their operations like easy market approach without any regulatory uncertainty, the survey of Indian pharma firms highlighted.
'The focus for value creation will be on all business segments.'
Researchers claim to have developed a new treatment for ovarian cancer that can increase the rate of tumour shrinkage and prolong the time until cancers recur.
Asset valuation consultancy sees brand value slip to $2.2 billion.
Informing about his decision, Maurya said in a tweet in Hindi, 'Due to the attitude of gross neglect towards Dalits, backwards, farmers, unemployed youth and small and medium-sized traders, I am resigning from the council of ministers of Yogi (Adityanath) of UP.'
'Nobody is attacking the company or the vaccine.' 'The concerns are about the process and the lack of transparency.'
The government plans to rationalise trade margins for many other medical devices, besides stents and knee implants.
The joint entity will have a market share of nine per cent in India. Analysts tracking the company said one of the key outcomes of the merger would be to create a single brand entity of Sun and the Ranbaxy brand would eventually dissolve.
Vice President Mike Pence said Trump had authorised a ban on entry of foreign nationals who travelled to Iran in the last 14 days. The United States also advised its citizens not to travel to parts of South Korea and Italy, from where reports of coronavirus have appeared.
According to an official statement, the FDA has determined that the Moderna COVID-19 vaccine has met the statutory criteria for issuance of an emergency use authorisation (EUA).
A look at the top tweets from your favourite Bollywood celebrities.
There are a number of vaccine candidates already in clinical trial and a few out of those candidates have completed phase 1/2 status, he said, adding that there are trials that will be going into phase three sometime at the end of July and then others will follow in the months of August, September and October.
The S&P BSE Sensex surged 217 points to end at 25,736.
Maggi re-entered the market on November 9.
'The Khalistanis get bulk of the money from abroad.' 'Where did Amritpal's Mercedes come from, which costs well over Rs 60 lakhs?' 'Where does his fleet of vehicles come from?' 'Local Punjabis can certainly not contribute this kind of money.'
GE Healthcare has already filed five global patents for its design.
An International Policy Network report in 2010 found that seven per cent of drugs bought from wholesale traders were substandard, and 3.6 per cent of the drugs from traders contained no active ingredient whatsoever.
Broader market outperformed with the S&P BSE Midcap index adding 0.7%, while S&P BSE Smallcap index gained 0.6%.
A team at Bristol University used recently developed techniques to validate that the vaccine accurately follows the genetic instructions programmed into it by the Oxford University team.
The Ranbaxy experience has made multinational corporations more cautious about Indian acquisitions in general
The ICMR is working on a war footing to develop the testing ecosystem -- especially for the screening blood tests. NIV, Pune, is in the process of validating antibody-based screening kits.
Instant noodle from Nestle is not the first food brand in India to have faced a tough time though
AstraZeneca Plc and the University of Oxford are facing questions about their Covid-19 vaccine and whether regulators would quickly authorise its emergency use after the pharma company acknowledged an error in the vaccine dosage received by some participants and other irregularities and omissions, according to the New York Times.
The new test it will enable rapid testing amongst more people easily.
CBD oil, found in marijuana, is gaining popularity for its pain-relieving properties. It's now legally available in India
Consultants are working with various teams on manufacturing, R&D, etc, to assess per-month productivity of each department.
Sun Pharma's offer was tempting because Ranbaxy was too busy fighting fires in the US to concentrate on operations.
Upset over the Devyani Khobragade episode, India on Wednesday raised with the United States its concerns over "trafficking" visas issued to family members of Sangita Richard, the absconding maid of the Indian diplomat whose arrest had triggered a row between the two countries.
The Indian Council of Medical Research will start national-level sero surveys to assess the spread of Covid-19 and all states/Union territories should also be encouraged to conduct them so that information from all geographies can be collected, the Union health ministry said on Friday.
As the global debate on booster shots gathers momentum, several scientists in New Delhi said the priority must be to ensure that more people are inoculated with at least their first jab.
Indian companies have made acquisitions of $1 billion so far in January
In 2008, Daiichi Sankyo had bought the entire 34.82 per cent stake in Ranbaxy from its promoters, Malvinder Mohan Singh and family, for $4.2 billion. Currently, Singh is executive chairman of Fortis Healthcare.
The matter is now expected to be raised with the PMO.
Earning woes drag markets lower; TCS, HUL lead fall.
TCS, Infosys and Wipro were down 0.4-2% each. Capital goods majors also ended lower with L&T and BHEL down 1.4-3.9% each.
Zuckerberg leads the pack with a net worth of $47.1 billion.
Investors will maintain a cautious stance.
In March, he had said that China is responsible for the spread of the novel coronavirus and called the COVID-19 as the "Chinese Virus".
With the threat of COVID-19 pandemic continuing to loom over the world, the Ministry of Ayush has come out with a comprehensive document putting forth the concept of 'holistic health'.
The deadly virus, which has killed over 5,000 people globally, has spread to 46 of the 50 US states.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances